Biofrontera Inc.NASDAQ: BFRI

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Oct 31, 2024 · Issued by Biofrontera Inc.

Watch Biofrontera explain itBiofrontera Inc. (BFRI) Q2 2026 Earnings Call · Replay · Aug 13

First Phase 3 PDT study in patients with sBCC in the United States.
Primary and secondary endpoints all highly statistically significant p

Company analysis